A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 18 years old - evidence of active Thrombotic Microangiopathy (TMA)

Exclusion Criteria:

- previous or ongoing treatment with complement inhibitors, including anti-C5 antibody - ADAMTS13 deficiency - positive test for Shiga toxin * direct Coombs test - had a bone marrow transplant or hematopoietic stem cell transplant, or a heart, lung, small bowel, pancreas or live transplant

Conditions & Interventions

Interventions:
Drug: Iptacopan
Conditions:
Blood Disorders, Kidney, Prostate & Urinary, Rare Diseases
Keywords:
Clinics and Surgery Center (CSC)

More Information

Description: To evaluate the efficacy and safety of iptacopan at a dose of 200 mg twice a day for 52 weeks in patients with atypical hemolytic uremic syndrome (aHUS).
Study Contact: Karen Omlung - seve0024@umn.edu
Principal Investigator: Nattawat Klomjit
Phase: PHASE3
IRB Number: STUDY00020503